Conference abstractPublished 28 Apr 2017
Preclinical development of biopharmaceuticals (r-DNA Products)
Intox Pvt. Ltd., India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Biopharmaceuticals are an important component of pharma industry & have grown exponentially in the last decade. The growth is driven by factors such as growing pressure for affordable product development, advances in biochemical and molecular biology instrumentation, growing demand for biosimilar drugs to address ever growing chronic diseases, increasing number of off-patented therapeutics and monoclonals. Great successes were achieved and multiple life-altering therapies were developed for indications like cancer, rare genetic diseases, and immune disorders. Significant guidance has been released by regulatory agencies to help the rational and scientifically based development of these complex products. The goal of preclinical development of biosimilar is to demonstrate that, the drug is âÂ?Â?highly similarâÂ?Â? to the reference biologic product in terms of âÂ?Â?Safety, Efficacy and QualityâÂ?Â?. Monitoring biopharmaceutical drug safety deserves special attention. In this presentation, challenges in the preclinical development of biologicals (particularly âÂ?Â?BiosimilarsâÂ?Â?) will discussed in short. Key features of biotechnologyderived molecules (Biosimilars including Vaccines), how they compare to traditional chemical drugs, and the impact these features on preclinical safety testing during their development will also be discussed.
Subjects
ToxicologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalToxicology: Open Access
- SubjectToxicology
- BylineArticles whose byline prints “Mukul P Pore”